Correction to: European Journal of Nuclear Medicine and Molecular Imaging
On page 4 of the original version of this article, the text "Eight (29%) of the patients had significant FDG-avid disease (i.e. with intensity above liver parenchyma) prior to treatment" needs to be corrected to "Eighty-nine percent of the patients had significant FDG-avid disease (i.e. with intensity above liver parenchyma) prior to treatment".
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found at https://doi.org/10.1007/s00259-017-3821-2
Rights and permissions
About this article
Cite this article
Thang, S.P., Lung, M.S., Kong, G. et al. Correction to: Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis. Eur J Nucl Med Mol Imaging 45, 323 (2018). https://doi.org/10.1007/s00259-017-3886-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00259-017-3886-y